Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.32 |
| ▸ | HPGDS | O60760 | 2/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932995 | 0.97 | GPR119 (0.33) | GPR119DGAT1HPGDSCHEK2ALDH1A1 | |
| SCHEMBL933621 | 0.96 | HPGDS (0.34) | GPR119DGAT1HPGDSCHEK2 | |
| SCHEMBL1891182 | 0.94 | CHEK2 (0.33) | GPR119CHEK2ALDH1A1MEN1LMNA | |
| SCHEMBL1888132 | 0.93 | HPGDS (0.34) | GPR119DGAT1HPGDSCHEK2ALDH1A1 | |
| SCHEMBL932651 | 0.92 | DGAT1 (0.36) | GPR119DGAT1CHEK2ALDH1A1MEN1 | |
| SCHEMBL12661154 | 0.91 | CHEK2 (0.34) | GPR119DGAT1CHEK2ALDH1A1MEN1 | |
| SCHEMBL933407 | 0.91 | DGAT1 (0.32) | GPR119DGAT1HPGDSCHEK2ALDH1A1 | |
| SCHEMBL12661219 | 0.90 | GPR119 (0.36) | GPR119DGAT1CHEK2ALDH1A1MEN1 | |
| SCHEMBL1888626 | 0.89 | DGAT1 (0.37) | GPR119DGAT1CHEK2ALDH1A1MEN1 | |
| SCHEMBL933689 | 0.89 | HPGDS (0.33) | GPR119DGAT1HPGDSCHEK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | GPR119 2249/4885DGAT1 1994/4885HPGDS 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.